In patients with 350 CD4 cells/mm3 or more, the decision to begin therapy should be individualized based on the presence of comorbidities, risk factors for progression to AIDS and non-AIDS diseases, and patient readiness for treatment. This evidence concerns the gene CD4 and AIDS.